[Refractory thyroid cancers].

Abstract

Refractory thyroid cancers include medullary and differentiated cancers with locally advanced disease that is not amenable to surgery or with distant metastases, differentiated thyroid carcinomas being refractory to radio-iodine treatment and all anaplastic carcinomas. These carcinomas are rare, with an estimated incidence in France of 350 new cases per year. Their management may benefit from the TUTHYREF network. Kinase inhibitors inhibit kinases of the VEGF receptors, and this inhibits angiogenesis, and some of these agents also inhibit other kinases of the MAPkinase pathway. These inhibitors are effective in differentiated and medullary thyroid cancers, and induce a partial response or a long-term stabilisation in more than half of patients. Their toxicity is significant and these treatments should be given only to selected patients with locally advanced or metastatic disease, with progression or with clinical symptoms.

• Authors: Martin Schlumberger, Cécile Chougnet, Eric Baudin, Sophie Leboulleux, pour le réseau Tuthyref
• Journal: Presse medicale (Paris, France : 1983) (Presse Med) Vol. 40 Issue 12 Pt 1 Pg. 1189-98 (Dec 2011) ISSN: 2213-0276 [Electronic] France
• Vernacular Title: Cancers réfractaires de la thyroïde.
• PMID: 22078085 (Publication Type: Evaluation Study, Journal Article, Review)
• Copyright: Copyright © 2011. Published by Elsevier Masson SAS.

Chemical References

• Antineoplastic Agents
• Protein Kinase Inhibitors
• Receptors, Vascular Endothelial Growth Factor

Topics

• Adenocarcinoma, Follicular
• Antineoplastic Agents (adverse effects, therapeutic use)
• Carcinoma (drug therapy, genetics, pathology)
• Carcinoma, Neuroendocrine
• Disease Progression
• Drug Resistance, Neoplasm (genetics, physiology)
• Humans
• Protein Kinase Inhibitors (adverse effects, therapeutic use)
• Receptors, Vascular Endothelial Growth Factor (antagonists & inhibitors)
• Thyroid Neoplasms (drug therapy, genetics, pathology)
• Treatment Failure